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Abstract
Purpose: Given the progress of fluorescence diffuse optical tomography (fDOT) technology,
here, we study the additional benefits provided by multimodal PET/fDOT imaging by comparing
the biodistribution of 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) in tumors with three fluorescent
probes: a glucose analog, a protease activatable optical probe, and a ligand of αvβ3 integrin.
Procedures: Sequential fDOT/PET/computed tomography (CT) imaging of mice was performed
with a custom multimodal mouse support that allows the subject to be transferred between the
fDOT and the PET/CT scanners. Experiments were performed in xenografted tumor models
derived from the human breast cancer line MDA-MB 231 and compared to ex vivo analysis.
Results: The three-dimensional signals showed that the fluorescent glucose analog is not
colocalized with [18F]FDG, raising questions about its use as a surrogate probe of the PET
tracer. Fusion of [18F]FDG with the other fluorescent probes showed evidence of high variability
both for the protease activity and the αvβ3 integrin expression during tumor growth.
Conclusion: The added value of hybrid PET/fDOT over the two modalities was demonstrated for
cross-validation of probes and for better characterization of tumor models.
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is largely used to monitor the glucose metabolism of
tumors by positron-emission tomography (PET) imaging.
Indeed, many tumors exhibit a higher uptake of [18F]FDG
compared to most normal organs or tissues because cancer
cells usually overexpress glucose transporter (GLUT)
proteins and have increased levels of active hexokinase [1].
Hence, [18F]FDG PET imaging is now routinely used in
clinics for the evaluation of several neoplasms, both before
and after therapy, helping to stage tumors and monitor tumor
response [2]. Similarly, [18F]FDG PET imaging has been
increasingly used in preclinical research for both basic
research and drug development [3, 4]. However, it is well
known that cancer is a multistep and multiparametric disease
[5, 6]. Therefore, there is an increasing demand to
simultaneously study glucose metabolism in combination
with other factors, such as hypoxia, tissue remodeling, or
angiogenesis. Such multimodal imaging can be particularlyCorrespondence to: Frédéric Ducongé; e-mail: frederic.duconge@cea.fr
useful to study the effect of a therapy or the function of a
speciﬁc oncogene to the development of tumors in small
animal models.
To address this issue, several PET tracers have been
developed to highlight different physiological processes of
tumors [2]. However, the coregistration of [18F]FDG with
another PET tracer is limited since tracers have to be
injected sequentially, waiting the decay of the previously
injected isotope without moving the animal. Another
possibility is to fuse [18F]FDG PET with information
originating from another imaging modality. So far, PET
imaging has been fused with different imaging modalities,
mostly X-ray computed tomography [7] (CT) and, more
recently, magnetic resonance imaging [8] (MRI). However,
although CT and MRI display high-spatial resolution
imaging, they lack contrast agents to perform functional
imaging and are mostly used to measure tumor's morpho-
logic features (i.e., size, shape, or blood vessel density).
Recently, optical techniques have been increasingly used
for small animal imaging. However, the fusion of PET with
these new modalities of imaging has not been very
developed so far. This could be explained by the fact that
most optical imaging systems are currently used to perform
planar imaging as opposed to three-dimensional (3D)
imaging. The signal detected by such two-dimensional
(2D) systems is strongly affected by scattering of light in
tissue and can only provide semiquantitative measurements
from 2D images. To address this issue, ﬂuorescence diffuse
optical tomography (fDOT) technique, also known as
ﬂuorescence molecular tomography, has been developed
since the 1990s by several groups [9–13]. This technology
employs instruments that operate in a transillumination
excitation mode and uses sophisticated reconstruction
algorithms [10] for reconstructing a 3D ﬂuorescence signal
with similar resolution as PET. Although, fDOT is still only
able to perform imaging inside tissue a few centimeters in
depth, it is perfectly adapted to in vivo imaging in mice.
Therefore, fDOT systems dedicated to small animals have
considerably evolved in less than 10 years, from systems in
which the animal was immersed inside an index matching
ﬂuid [13] to systems where the animal was not immersed,
but still compressed between two transparent plates [14] and,
ﬁnally, to contact-free systems [15]. Our group developed a
simple method to fuse small animal PET and CT imaging
with fDOT. This method uses a mouse support with a
transparent plexiglas plate that can be moved between all the
three different imaging modalities and a dedicated software
that allows coregistration of independently acquired images
[16]. In a previous study, we calibrated a contact-free fDOT
apparatus by using this method for correlating its measures
with quantitative values obtained by PET, as a gold
standard. Our results clearly demonstrated the accuracy of
fDOT to quantify the biodistribution of probes inside mice,
in a manner comparable to PET for concentrations ranging
from 3 nM to 1 μM [16]. A similar correlation between PET
and fDOT imaging was also demonstrated by Nahrendorf et
al. [17], using another fDOT system where the animal is
compressed between transparent plates.
In addition of validating fDOT apparatus, these results
prompted us to evaluate the additional beneﬁts of fDOT/PET
imaging in other applications. Here, we use fDOT/PET to
complement [18F]FDG PET imaging of a tumor xenograft
with three different near-infrared (NIR) ﬂuorescent probes:
(1) a ﬂuorescent labeled glucose analog, (2) a protease
activatable probe, and (3) a ﬂuorescent probe targeting the
αvβ3 integrin. These studies were conducted to demonstrate
the additional beneﬁts of combined fDOT and PET imaging
for cross-validating probes and highlighting different tumor
processes in parallel inside the same subject.
Materials and Methods
Cell Culture
Human breast cancer MDA-MB-231 cells were grown in Dulbec-
co's modiﬁed Eagle’s medium supplemented with 10 % fetal calf
serum, L-glutamine (2 mM), penicillin (100 U/ml), and streptomy-
cin (100 μg/ml) at 37 °C in a 5 % CO2 humid atmosphere. All
culture reagents were purchased from Invitrogen (Cergy Pontoise,
France). Green ﬂuorescent protein (GFP)-expressing cells were
obtained by transduction of cells with lentiviruses encoding for
GFP.
Mice Models
All animal use procedures were in strict accordance with the
recommendations of the European Community (86/609/CEE) and
the French National Committee (décret 87/848) for the care and use
of laboratory animals. All used mice were female nude mice
weighing approximately 23 g and housed under standard conditions
with food and water ad libitum. To minimize the autoﬂuorescence
background signals, the mice were nourished with chlorophyll-free
diet (Diet 210, SAFE, France) for 2 weeks before imaging. For the
tumor xenograft model, a syringe was prepared containing 106
tumor cells MDA-MB231 in a volume of 100 μl of phosphate-
buffered saline (PBS) with 100 μl of Matrigel (BD Bioscience, Le
Pont de Claix, France) at 0 °C. Cells were subcutaneously
implanted between the omoplates of anesthetized mice and allowed
to grow for several weeks until the desired tumor size was reached.
For injection of probes and during imaging experiments, mice were
anesthetized with isoﬂurane—1.25 % in a 1:3 mixture of O2 and
air.
PET/fDOT/CT Multimodal Imaging
For all experiments, ~7.4 MBq (200 μCi) of [18F]FDG were
intravenously (IV) injected in anesthetized mice prior to imaging.
For the ﬁrst experiment, 2 nmol of the IRDye800CW 2-DG (Licor,
Lincoln, Nebraska, USA) probe were IV administrated 24 h prior to
[18F]FDG. The same protocol was used for the imaging of
cathepsin activity using the probe ProSense680 (Perkin Elmer,
Waltham, Massachusetts, USA). For the imaging of αvβ3 integrin,
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5 nmol of the Arg-Gly-Asp (RGD)-based ﬂuorescent probe
Angiostamp (Fluoptics, Grenoble, France) was IV administrated
4 h before imaging.
The imaging procedure started with a PET scan 60 min after the
injection, in accordance with the stabilization of the [18F]FDG
inside the tumors. The mouse was, thereafter, transported and
positioned in the fDOT instrument by means of a custom-made
mouse support, all without moving the mouse in regard to the
support. A local fDOT scanning was performed in the tumor area.
Finally, for the case of ProSense680 and Angiostamp, the mouse
was placed into a CT instrument for X-ray structural imaging.
PET acquisitions were performed using a MicroPET Focus 220
scanner (Siemens-Concorde Microsystems). The PET reconstruc-
tions were performed using the MicroPET Manager software
(Siemens-Concorde Microsystems), based on a ﬁltered back-
projection algorithm. Images were reconstructed with the following
frame durations: 2×15 min, suitable for the monitoring of [18F]
FDG. The dimensions of reconstruction volumes were 256×256×
95×(number of time frames) with a voxel size of 0.475×0.475×
0.796 mm3. For the fDOT measurements, a free-space ﬂuorescent
tomographic system, operating in the transillumination mode
(Cyberstar, France), was used [18]. This imager incorporates a
continuous wave laser mounted on a two-dimensional motorized
stage for the optical scanning of the targeted region. A sensitive
charge-coupled device (CCD) camera (C4742, Hamamatsu, Japan)
with an objective lens focusing on the other side of the subject
acquires images at the different laser positions. The system
incorporates a band pass emission ﬁlter 720±15 nm (HQ720/30,
Chroma Technology, USA) for the detection of the ProSense680
and Angiostamp ﬂuorophores and a 770-nm-long pass ﬁlter
(770ALP Emitter XF3115, Omega Filters, USA) for the detection
of IRDye800CW 2-DG. Since the fDOT scanner is mainly suited
for Cy5.5-like ﬂuorophores, we chose to test its sensitivity for
imaging the 800-nm IRDye800CW 2-DG. In experiments where
capillaries of controlled concentrations of the probe were imaged
after being subcutaneously positioned in mice, the concentration
limit at this wavelength was found in the order of 0.6 μM which is
much lower than typical IRDye800CW 2-DG signals in tumors (in
the range between 2 and 8 μM).
The tumor scan consisted of a square grid of 6×6 sources in
steps of 2 mm. The geometry of the mouse was reconstructed with
the use of a laser pattern method [16]. A 2×2 binning is applied on
the camera pixels, and typical detector areas are in the order of 13×
13 mm2 covering the targeted tissue area. As soon as the collection
of projections was completed, the data were mathematically
processed to give a 3D image of the ﬂuorescence activity inside
the mouse body (voxel size of 0.67×0.67×1 mm3) according to the
procedure described in detail by Hervé et al. [18]. The resolution of
the reconstructed signal is in the order of 1 mm3 [16].
The CT measurements were performed using the SkyScan 1178
high-throughput microCT (Skyscan, Kontich, Belgium). A total of 360
images were recorded with an angular step of 1°. The reconstructions
were performed with the NRecon software (Skyscan, Kontich,
Belgium). For each reconstruction, a total of 509 coronal slices were
reconstructed with 0.1609-mm spatial interval between adjacent slices.
Coregistration Toolbox
The mouse-supporting system contained four multimodal sources
of contrast (model MMS10-068-1U; Isotope Product Laboratories,
Valencia, CA, USA), which can serve as ﬁducial points for the
coregistration of independently acquired images. For the coregis-
tration of images between PET, fDOT, and CT, an in-house toolbox
was built under the platform of the BrainVISA imaging software
(http://brainvisa.info/index_f.html). The PET image from each
mouse has been chosen as reference, and corresponding CT and
optical images have been spatially aligned to it. First, CT and
optical images have been ﬂipped in order to ﬁt with the orientation
of microPET image. Once the ﬁducial markers are identiﬁed, their
position is manually outlined. Images from each modality are then
automatically coregistered with respect to the four ﬁducial marker
positions by a least squares regression. From this regression, the
optimal rotation and translation parameters can be calculated and
stored as rigid body transformation matrix [16]. The errors of this
coregistration procedure are below the resolution limit of PET and
fDOT [19]. The fusion of images was also performed by using the
BrainVISA software with the aid of the coregistration transforma-
tion matrices. Volumes of interest (VOIs) were drawn manually and
were applied to each modality by the transformation matrices
calculated from the process of image coregistration.
Ex Vivo Analysis
At the end of the in vivo imaging protocol, mice were euthanatized
by an overdose injection of sodium pentobarbital. For immunohis-
tochemistry, the xenografts were removed surgically; incubated in
zinc ﬁxative (BD Pharmingen, #552658) at 4 °C during 24 h and
then in 20 % sucrose with 4 % sodium phosphate-buffered
paraformaldehyde (Labonord, #11699408; pH 7.4, 0.1 M) at 4 °C
during 24 h, before being frozen in isopentane; and stored at −80 °
C. Sections of 5-μm thickness were prepared on a cryostat, ﬁxed in
4 % sodium phosphate-buffered paraformaldehyde, and permeabl-
ized in methanol–acetone (1:1, −20 °C, 5 min) and in phosphate-
buffered saline 0.1 % triton×100 (room temperature (RT), 5 min).
After saturation of nonspeciﬁc binding sites with solution contain-
ing 5 % bovine serum albumin and 0.5 % Tween 20, tissues were
incubated with primary antibody rabbit antihuman/rat GLUT-1
(Thermo Scientiﬁc, #RB-9052-P0, 1/200, RT, 1 h) diluted in
saturation solution. Following PBS washes (three times), sections
were incubated with AF546-labeled goat anti-rabbit IgG (H + L)
(Invitrogen, A11010, 1/1000, RT, 30 min) diluted in saturation
solution. Following three additional washes, sections were mounted
with a Prolong Antifade kit (Molecular Probes, Invitrogen,
P36930). Multichannel panoramic images were acquired at×100
magniﬁcation on an epiﬂuorescence-inverted microscope Axio
Observer Zeiss (Zeiss, Germany) equipped with motorized stage.
For whole animal axial imaging, the euthanized mice were
frozen at −80 °C for several hours. Then, whole-body axial sections
at the level of the tumor of 150-μm thickness have been cut with a
Leica CM 3050 cryostat (Leica Microsystems, Wetzlar, Germany).
Whole-body sections subject to deforming, and therefore, care has
been taken to select the least deformed sections. Five equally
spaced axial sections, covering the whole tumor lump, were chosen
and placed on microscope glass slides. The sections were placed in
a planar imaging system (Photon Imager, Biospace, France) for the
GFP imaging, in the planar imaging mode of the fDOT imager for
the whole animal section imaging of ProSense680 and Angiostamp
and in the planar ﬂuorescence imager FluoBeam800 (Fluoptics,
Grenoble, France) for the imaging of IRDye800CW 2-DG.
Coregistration between the independently taken images has been
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performed by using the four edges of the glass slides as ﬁducial
markers.
Results
Fusion of [18F]FDG PET Imaging with fDOT
Imaging of Fluorescently Labeled IRDye800CW
2-DG
In the past decade, several ﬂuorescent derivatives of 2-
deoxy-D-glucose (2-DG) have been developed to provide a
mimicking of [18F]FDG that can be used for ﬂuorescence
imaging of tumors [20]. One of these derivatives,
IRDye800CW 2-DG, a 2-DG labeled with a NIR dye,
demonstrated, using planar ﬂuorescence imaging, high in
vivo uptake by various tumors implanted subcutaneously in
immunodeﬁcient mice [21]. In these studies, it was observed
that the ﬂuorescent tracer provides a better contrast 24 h
postinjection, while in the case of [18F]FDG, high contrast
are generally achieved only 30 min to 2 h postinjection.
To study the difference and similarities between these
both tracers with 3D imaging, we coregistered images
obtained by fDOT using IRDye800CW 2-DG with [18F]
FDG PET images. As a model, we used subcutaneous tumor
xenografts of human breast cancer cells (MDA-MB-231)
subcutaneously implanted in nude mice. IRDye800CW 2-
DG was ﬁrst intravenously injected in mice (n06) bearing
tumors of a size around 519±223 mm3 (diameter 9.6±
1.2 mm). After 24 h, mice were IV injected with [18F]FDG
just before a sequential fDOT/PET imaging acquisition.
Results showed that each tracer demonstrated a higher
uptake in tumors compared to surrounding tissue, leading
to a clearly detectable imaging contrast for both PET and
fDOT imaging (Fig. 1a, b, e, and f). However, the fused
fDOT/PET images showed that IRDye800CW 2-DG and
[18F]FDG displayed a signiﬁcant different localization in the
tumors (Fig. 1c, d, g, and h). [18F]FDG had a higher
Fig. 1. Imaging using IRDye800CW 2-DG and [18F]FDG. (a) Sagittal view of the [18F]FDG-PET signal of a xenografted mouse
showing high activity at the site of the xenografted tumor (tumor volume of 775 mm3). The arrow pinpoints the position of the
tumor as identified by [18F]FDG. (b) The fDOT IRDye800CW 2-DG signal at the corresponding sagittal plane. The area, in which
the fDOT reconstruction is performed, is depicted by a dotted whiteframe. (c) Fused PET/fDOT sagittal image originating from
the images of (a) and (b). (d) Sagittal view of the volumes occupied by the fDOT (blue) and PET (red) signal rendered to the 3D
surface of the mouse (gray). (e, f, and g) The equivalents of (a), (b), and (c) are presented, but in the axial view; (h) Axial view of
fused fDOT/CT image at the level of the tumor. (i) Immunohistochemical labeling for GLUT-1 expression (in red) in the excised
tumor. Nuclei (in blue) are counterstained with DAPI. (j) Fluorescence image shows the biodistribution of IRDye800CW 2-DG
signal in the same section than (i). (k) Image of the fusion of (i) and (j) shows the co-localization of the GLUT-1 and the
IRDye800CW 2-DG. (l) White light image of the whole animal axial section.
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accumulation at the periphery of the tumor, while it had a
lower uptake in the center of the xenografts.
Nevertheless, it has been proven in vitro that the uptake
of IRDye800CW 2-DG by cancer cells can be speciﬁcally
blocked by an antibody against GLUT1 glucose transporter
or by excess of unlabeled 2-DG or D-glucose [21]. Hence,
we decided to compare the localization of IRDye800CW 2-
DG with the expression of GLUT1 by immunohistochem-
istry. Very low expression of GLUT1 was detected at the
border of the tumor, while GLUT1 seems to be heteroge-
neously expressed in the center of the tumor. Interestingly, a
good colocalization was also observed between GLUT1 and
the IRDye800CW 2-DG (Fig. 1i–k).
Fusion of [18F]FDG PET Imaging with fDOT
Imaging of Cathepsin Activity
In another set of experiments, [18F]FDG PET imaging was
combined with fDOT imaging of protease activity. Extra-
cellular proteases are produced either by cancer cells
themselves or by neighboring host cells. They participate
to cellular invasion of basement membranes and connective
tissue stroma as well as in the formation of new blood vessels
during angiogenesis to support the burgeoning energy demands
of rapidly growing tumors [22]. Hence, it can be interesting to
study in parallel glucose metabolism and protease activity of
tumors. For this purpose, we use an activatable optical probe
(ProSense680, excitation maximum at 680 nm and emission
maximum at 700 nm), which has the property of being
optically silent (quenched) in its native state and can be
speciﬁcally degraded by the cathepsins B, L, and S and
plasmin, thereby generating anNIR ﬂuorescence signal [23]. In
that case, the ﬂuorescence signal is not only indicative of the
presence of this class of proteases but also of their activity.
Nude mice, bearing subcutaneous tumor xenografts of
human MDA-MB-231 cells stably transformed to express
green ﬂuorescent protein, were ﬁrstly injected intravenously
with ProSense680. Then, after 24 h, a second IV injection of
[18F]FDG was performed followed by a sequential fDOT/
PET/CT acquisition. From the fused fDOT/PET/CT images
(n03), we observed that, in contrary to the IRDye800-2DG,
the cathepsin activity highlighted by ProSense680 was
predominantly located underneath the tumor highlighted by
FDG signal (Fig. 2a–h). To conﬁrm this data, whole-body
axial sections (~150 μm) of euthanized mice were performed
with a cryostat at the level of the tumor and imaged by
planar ﬂuorescence imaging. In this case, the localization of
protease activity was compared with the localization of
tumor cells detected by their GFP signal. The distribution of
ProSense680 signal clearly localized at the margins of the
tumor tissue (Fig. 2i–k). Hence, ex vivo imaging conﬁrmed
in vivo imaging, although PET and fDOT imaging have a
lower spatial resolution (~0.8 mm), which explains why
NIRF ﬂuorescent signal surrounding the tumor (Fig. 2g)
appears thicker in the in vivo fDOT images compared to the
ex vivo section analysis (Fig. 2g and k, respectively). These
results suggest that the protease activity is higher in the
stromal tissue surrounding the tumor than in the tumor
region rich in cancer cells.
The above results were obtained for the case of small
tumor having a volume measured by [18F]FDG PET imaging
around 63±24 mm3 (corresponding to tumor diameters of
4.8±0.6 mm). In order to study the evolution of protease
activity upon tumor growth, we performed the same fDOT/
PET imaging experiments on mice bearing more developed
tumor xenografts with an average size around 483±21 mm3
(n03). Although the tumor volume highlighted by [18F]FDG
was seven times larger, the same level of protease activity
was measured both in terms of the volume and the quantity
of ﬂuorescence signal (246±48 mm3 with 15.0±0.6 pmol
and 269±52 mm3 with 15.9±0.3 pmol for the small and the
big tumors, respectively). In contrast, the distribution of the
ﬂuorescence signal with respect to the [18F]FDG was
completely changed (Fig. 3). In that case, the ﬂuorescence
was mostly located inside the volume covered by the [18F]
FDG signal, while it was previously found beneath the
tumor. Up to 75 % of the ﬂuorescence signal was
colocalized with the [18F]FDG signal in comparison to
~7 % for small tumors. In conclusion, fDOT/PET imaging
suggests that the distribution of the protease activity could
vary during the tumor growth in this tumor model, although
its intensity is not increased.
Fusion of [18F]FDG PET Imaging with fDOT
Imaging of Fluorescent RGD-Based Probe
Several ligands (like peptides, antibodies, or aptamers) are
developed to target speciﬁc membrane proteins overex-
pressed in tumors. These ligands can be useful tools not only
to build contrast agents for cancer imaging but also to
speciﬁcally address drugs. fDOT imaging is still increasingly
used to validate these ligands in vivo [17, 24, 25]. However,
we hypothesize that the fusion of fDOT with PET imaging
can further improve this validation enabling a direct
comparison with PET tracers that are already used in clinic.
As a model, we decided to compare the distribution of the
RGD-based ﬂuorescent probe Angiostamp680 with [18F]
FDG PET imaging. The RGD peptide is known to bind the
αvβ3 integrin, a protein overexpressed at the surface of
certain cancer cells as well as at the surface of endothelial
cells during angiogenesis [26]. Angiostamp680 is composed
of four cRGD cyclopeptides linked to a cyclodecapeptide
platform labeled with a NIR ﬂuorescent dye [27]. This tracer
has previously demonstrated a rapid uptake in tumors after
IV injection and represents a promising contrast agent for
ﬂuorescence imaging-assisted surgery [28].
Angiostamp680 was IV injected in nude mice bearing
subcutaneous tumor xenografts of human MDA-MB-231
cells expressing GFP (n03). After 3 h, [18F]FDG was IV
injected just before a sequential fDOT/PET imaging
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acquisition. As previously described, we compared the
results obtained in nude mice bearing either small or big
tumors (~44±16 and ~230±20 mm3 calculated from [18F]
FDG imaging, respectively). Similarly to ProSense680, we
observed that the Angiostamp680 lies below the signal of
[18F]FDG for small tumors (Fig. 4a–h). The localization of
the probe mostly outside the tumor of small size was also
conﬁrmed ex vivo by planar ﬂuorescence imaging of whole-
Fig. 3. Distribution of the ProSense680 signal into tumors of different sizes. (a) Representative mesh volumes of ProSense680
(green) and [18F]FDG (red) for the case of a tumor with a volume of 50 mm3 (left) and 450 mm3 (right). (b and c) Histograms
evaluating the overlapping between the fluorescent signal and the [18F]FDG for quantity (b) and volume (c) for the cases of small
and big tumors (n03).
Fig. 2. Imaging using ProSense680 and [18F]FDG. (a) Sagittal view of the [18F]FDG-PET signal of a xenografted mouse
showing high activity at the site of the xenografted tumor (tumor volume of 50 mm3). The arrow pinpoints the position of the
tumor as identified by [18F]FDG. (b) Sagittal fDOT image of ProSense680 activity. The area in which the fDOT reconstruction
was performed is depicted by a dotted whiteframe. (c) Fused PET/fDOT image highlighting the distribution of the optical probe
with respect to the PET nuclear signal. (d) Reconstructed mesh volumes of fDOT signal (green) and PET signal (red) rendered to the
envelope of the mouse (gray); (e, f, and g) are the equivalent of (a), (b), and (c), but in the axial view. (h) Axial view of fused fDOT/CT
image at the level of the tumor. (i, j, k, and l) Planar images of axial animal sections. (i) GFP imaging enabling the visualization of the
GFP tumor cells. (j) Prosense680 imaging of the same section. (k) Fusion image of (j) and (k), showing that the cathepsin activity, is
predominantly located outside the tumor in accordance to the in vivo case. (l) White light image of the section.
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body axial sections (Fig. 4i–k). Contrary to the case of small
tumors, for big tumors, Angiostamp is much more localized
inside the volume covered by the [18F]FDG signal (~57.9±
10.9 % of the ﬂuorescence signal is colocalized with [18F]
FDG in contrary to only ~6.7±5.0 % for smaller tumor sizes,
see Fig. 5). However, compared to ProSense680, there is an
increase of the total amount of the Angiostamp680 in the
biggest tumors (450±148 pmol compared to 206±67 pmol,
for the big and the small tumors, respectively, Fig. 5),
although it was restricted in a similar or slightly smaller
volume (211±58 mm3 compared to 261±95 mm3). These
results suggest that, for this model, the αvβ3 integrin is
Fig. 4. Imaging using Angiostamp and [18F]FDG. (a) Sagittal slice of [18F]FDG PET at the level of the tumor (with a tumor
volume of 59 mm3). The arrow pinpoints the position of the tumor as identified by [18F]FDG. (b) Sagittal fDOT image of
Angiostamp. The area, in which the fDOT reconstruction is performed, is depicted by a dotted whiteframe. (c) Fused PET/fDOT
image highlighting the distribution of the optical probe with respect to the PET nuclear signal. (d) Reconstructed mesh volumes
of fDOT signal (green) and PET signal (red) rendered to the envelope of the mouse. (e, f, g, and h) The equivalent of (a), (b), (c),
and (d), but in the axial view. (i, j, k, and l) Planar images of axial animal sections. (i) GFP imaging enabling the visualization of
the GFP tumor cells. (j) Angiostamp imaging of the same section. (k) Fusion image of (j) and (k) showing that the protein activity
is predominantly located outside the tumor in accordance to the in vivo case. (l) White light image of the section.
Fig. 5. Distribution of the Angiostamp signal into tumors of different size. (a) Representative mesh volumes of Angiostamp
(yellow) and [18F]FDG (red) for the case of a tumor with a volume of 40 mm3 (left) and 220 mm3 (right). (b and c) Histogram
evaluating the overlapping between the fluorescent signal and the [18F]FDG for quantity (b) and volume (c) for the cases of small
and big tumors (n03).
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predominantly present in stromal tissue of small tumors, and
its expression is increased and much more localized inside
the tumor during its growth.
Discussion
Recently, the fusion of small animal PET imaging with 3D
ﬂuorescence diffuse optical tomography has been considered
as a promising approach [29, 30]. This method has been
previously used to calibrate fDOT using PET [16, 17]. Here,
we demonstrated that it could also be used for cross-
validation of imaging methods in both modalities or to
provide synergic information monitoring several molecular
pathways inside the same subject. As a proof of principle,
we studied the additional beneﬁts provided by the combina-
tion of fDOT with PET imaging by comparing the
biodistribution of [18F]FDG with three ﬂuorescent probes
in nude mice bearing tumor xenografts of MDA-MB-231
cells. [18F]FDG is the most used PET tracer in the world [1].
It provides information on glucose metabolism, which is
particularly useful for the detection of tumors as well as to
evaluate the effect of drugs. Since [18F]FDG is so valuable
in oncology, there is a high interest for developing
ﬂuorescent analogs of this tracer, which can be used for
small animals studies using optical methods.
Our ﬁrst experiment concerned the use of PET/fDOT
imaging to evaluate a ﬂuorescent 2-deoxy-glucose, the
IRDye800CW 2-DG. In our model, IRDye800CW 2-DG
was mostly localized at the center of the tumor, whereas
[18F]FDG was much more accumulated at the periphery of
the tumor. These results suggest that IRDye800CW 2-DG
may not be a surrogate probe for [18F]FDG. Accordingly,
Tseng et al. recently demonstrated in another tumor model
that the two probes show a quite different imaging of
treatment response [31]. Nevertheless, it should be noticed
that, as in our study, both probes were not compared at the
same time after injection (24 h and few minutes after
injection for IRDye800CW 2-DG and [18F]FDG, respective-
ly). Hence, further studies are warranted to compare this
ﬂuorescent tracer with [18F]FDG at the same time. However,
our results clearly demonstrates the beneﬁt of fDOT/PET
imaging for cross-validating or invalidating probes that are
developed to be used for the same applications in both
modalities. This approach could be particularly useful to
validate new ﬂuorescent probes that are developed for
clinical application in the ﬁeld of endoscopy and imaging-
guided surgery [32], comparing their distribution with PET
tracer already being used in patients.
Furthermore, fDOT/PET imaging can also provide addi-
tional beneﬁts using different probes in both modalities to
monitor in parallel different processes in vivo in the same
subjects. This approach can be especially useful to comple-
ment PET imaging with ﬂuorescent probes and imaging
approaches that were reserved to ﬂuorescence microscopy
until now. For instance, it is well known that ﬂuorescence of
dye can be modulated by their environment (pH,
hydrophobicity, etc.) or their interaction with nearby
molecules, leading to ﬂuorescence quenching or resonance
energy transfer. This property has been widely used to
develop so-called smart or activatable probes whose ﬂuo-
rescence can be switched “on” or “off” depending on a
molecular process, such as interaction with a biomarker or
degradation by a speciﬁc enzyme [23]. Such activatable
probes cannot be developed with radiotracers that are always
on and whose signal intensity is only dependent of isotope
decay. Here, we combined [18F]FDG imaging with a
ﬂuorescent activatable probe that allowed us to monitor the
activity of cathepsins. The activity of proteases is highly
regulated at posttranslational stages and requires speciﬁc
localization in cells as well as proteolytic maturation. Hence,
the use of ﬂuorescent activatable probes represents a
promising approach to study their enzymatic activity directly
in vivo compared to classical tracers that were developed to
study their expression. In our tumor model, there has been
some evidence that the activity of cathepsins does not
increase during tumor growth, but its localization was
changed. Therefore, fusion with [18F]FDG imaging allowed
us to observe that the ﬂuorescence was ﬁrst predominantly
located beneath the tumor before being mostly localized
inside the tumor during its growth. Such information would
be impossible to obtain with fDOT alone and could be
extended with many other ﬂuorescent activatable probes that
have been developed to monitor the activity of different
classes of proteases. Nevertheless, it is obvious that these
data will have to be complemented by other experiments to
verify that the signal does not correspond to a difference in
the diffusion of the ﬂuorescent probe inside the tumor. One
possibility can be provided once again by PET/fDOT
imaging using ﬂuorescent activatable probes radiolabeled
with positrons emitters. In that case, it might be possible to
normalize the ﬂuorescence signal corresponding to the
enzymatic activity with its distribution measured by PET.
Ongoing efforts are currently being conducted to develop
such multilabeled probes, also named monomolecular multi-
modality imaging agents [33].
Finally, other beneﬁts of PET/fDOT imaging might be to
study the effect of drugs in small animal models. For
instance, we were able to complement [18F]FDG PET with
fDOT imaging of a ﬂuorescent ligand that binds αvβ3
integrin. This protein is a known marker of angiogenesis. In
our model, results indicated an increase of ﬂuorescence
signal during tumor growth and a localization that was ﬁrst
predominantly below the tumor before expanding toward the
tumor during its growth. This result was expected since the
growth of tumors requires the formation of new blood
vessels from preexisting vessels, which are mainly present in
the stroma at the beginning of tumor growth. Therefore, such
PET/fDOT imaging might be useful to study the effect of
antiangiogenic therapies, measuring in parallel the effect on
an angiogenic marker and a metabolism marker.
In the present study, we used a simple approach by
moving a mouse support between different instruments.
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However, other groups are attempting to build an integrated
apparatus that can perform at the same time both optical and
nuclear imaging and at the same time using rings of separate
scintigraphy detectors and CCD cameras [34], combined
PET or gamma camera with an optical detector [35, 36] or
adaptation of a conical mirror-based fDOT inside the PET
gantry [37, 38]. Such instrument could improve fDOT/PET
imaging and will be useful to perform dynamic imaging.
Conclusions
Here, we demonstrate the additional beneﬁts of combined
fDOT and PET imaging, comparing the biodistribution of
FDG with three ﬂuorescent probes in xenograft tumor
models. This technique was used to show the advantages
of the combined technique for the evaluation of new optical
probes developed as surrogate markers to PET probes. We
also showed that fusion of PET with fDOT imaging could
provide unique beneﬁts to monitor in parallel different
physiological processes at the same time.
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